Government Launches National Drug Registry To Enhance Pharma Transparency

The Central Government officially launched the National Drug Registry (NDR) on July 1, 2026, marking a pivotal shift in pharmaceutical oversight. This initiative mandates a unique digital identity for every medicine manufactured and sold within India. By creating a centralized database, the government aims to ensure complete traceability of drugs from the factory floor to the pharmacy shelf.

The primary objective of the NDR is to combat the circulation of counterfeit medications and improve transparency across the supply chain. With a unique identifier, regulators can monitor the movement of drugs in real-time, ensuring that patients receive authentic, high-quality products. This system is expected to streamline inventory management for distributors and provide consumers with a reliable method to verify their medication.

This registry is part of a broader digital health infrastructure being built by the Ministry of Health. By integrating the NDR with existing digital health platforms, the government intends to create a seamless ecosystem where medical records and drug history are interconnected. This move is expected to significantly reduce the risk of medication errors and improve overall public health outcomes by ensuring that only verified, safe drugs reach the market.